This year’s American Association of Cancer Research (AACR) annual meeting saw a clutch of new studies on therapeutic vaccines that suggest the approach is starting to gain
Virus-based immunotherapy biotech Transgene is to begin clinical trials of its head and neck cancer drug candidate TG4050 after gaining regulatory clearance from the UK regulator.<
Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.